Clinical Trials
31
Active:0
Completed:10
Trial Phases
5 Phases
Phase 1:11
Phase 2:4
Phase 3:3
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (40.7%)Not Applicable
5 (18.5%)Phase 2
4 (14.8%)Phase 4
4 (14.8%)Phase 3
3 (11.1%)Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
Not yet recruiting
- Conditions
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Xiyanping injection+ antibiotic
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 1140
- Registration Number
- NCT06754865
Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: GP681 tabletDrug: GP681 Powder for Oral Suspension
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06678542
- Locations
- 🇨🇳
Women and Children's hospital of Ningbo University, Ningbo, China
Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: GP681 10mg/20mg/40mg
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT06643156
- Locations
- 🇨🇳
Ningbo Women and Children's hospital, Ningbo, Zhejiang, China
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Phase 3
Recruiting
- Conditions
- Influenza
- Interventions
- Drug: GP681 SimulantDrug: GP681 40mg
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 748
- Registration Number
- NCT06574503
- Locations
- 🇨🇳
Shulan (Hang Zhou) Hospital, Hanzhou, China
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
Phase 3
Recruiting
- Conditions
- Influenza, Human
- Interventions
- Drug: GP681 SimulantDrug: GP681 40mg
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 328
- Registration Number
- NCT06573008
- Locations
- 🇨🇳
The people's Hospital of Chizhou, Chizhou, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found